References
1. de Franchis R, Bosch J, Garcia-Tsao G, Reiberger T, Ripoll C, Baveno
VIIF. Baveno VII - Renewing consensus in portal hypertension.Journal of hepatology 2022; 76 (4): 959-74.
2. Qi X, Berzigotti A, Cardenas A, Sarin SK. Emerging non-invasive
approaches for diagnosis and monitoring of portal hypertension.The lancet Gastroenterology & hepatology 2018; 3 (10):
708-19.
3. Villanueva C, Albillos A, Genesca J, et al. beta blockers to prevent
decompensation of cirrhosis in patients with clinically significant
portal hypertension (PREDESCI): a randomised, double-blind,
placebo-controlled, multicentre trial. Lancet 2019;393 (10181): 1597-608.
4. Abraldes JG, Bureau C, Stefanescu H, et al. Noninvasive tools and
risk of clinically significant portal hypertension and varices in
compensated cirrhosis: The ”Anticipate” study. Hepatology 2016;64 (6): 2173-84.
5. Banini BA, Patel S, Yu JW, et al. Derivation and Validation of a
Model to Predict Clinically Significant Portal Hypertension Using
Transient Elastography and FIB-4. Journal of clinical
gastroenterology 2022.
6. Kim TY, Jeong WK, Sohn JH, Kim J, Kim MY, Kim Y. Evaluation of portal
hypertension by real-time shear wave elastography in cirrhotic patients.Liver international : official journal of the International
Association for the Study of the Liver 2015; 35 (11): 2416-24.
7. Kitson MT, Roberts SK, Colman JC, Paul E, Button P, Kemp W. Liver
stiffness and the prediction of clinically significant portal
hypertension and portal hypertensive complications. Scandinavian
journal of gastroenterology 2015; 50 (4): 462-9.
8. Jiang FR, Yan HD. Risk factors of clinically significant portal
hypertension in patients with compensated liver cirrhosis based on
hepatic venous pressure gradient. Zhonghua gan zang bing za zhi =
Zhonghua ganzangbing zazhi = Chinese journal of hepatology 2021;29 (10): 995-1000.
9. Jansen C, Bogs C, Verlinden W, et al. Shear-wave elastography of the
liver and spleen identifies clinically significant portal hypertension:
A prospective multicentre study. Liver international : official
journal of the International Association for the Study of the Liver2017; 37 (3): 396-405.
10. Dajti E, Ravaioli F, Marasco G, et al. A Combined Baveno VII and
Spleen Stiffness Algorithm to Improve the Noninvasive Diagnosis of
Clinically Significant Portal Hypertension in Patients With Compensated
Advanced Chronic Liver Disease. The American journal of
gastroenterology 2022; 117 (11): 1825-33.
11. Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement:
an updated guideline for reporting systematic reviews. BMJ 2021;372 : n71.
12. Whiting PF, Rutjes AW, Westwood ME, et al. QUADAS-2: a revised tool
for the quality assessment of diagnostic accuracy studies. Annals
of internal medicine 2011; 155 (8): 529-36.
13. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring
inconsistency in meta-analyses. BMJ 2003; 327 (7414):
557-60.
14. Jiang W, Wang J, Shen X, et al. Establishment and Validation of a
Risk Prediction Model for Early Diabetic Kidney Disease Based on a
Systematic Review and Meta-Analysis of 20 Cohorts. Diabetes Care2020; 43 (4): 925-33.
15. Liu C, Li J, Wong YJ, et al. ABC: a novel algorithm to stratify
decompensation risk in patients with compensated advanced chronic liver
disease (CHESS2108): an international, multicenter cohort study.Hepatology international 2022; 16 (5): 1105-15.
16. Liu C, Cao Z, Yan H, et al. A Novel SAVE Score to Stratify
Decompensation Risk in Compensated Advanced Chronic Liver Disease
(CHESS2102): An International Multicenter Cohort Study. The
American journal of gastroenterology 2022; 117 (10): 1605-13.
17. Bosch J, Abraldes JG, Berzigotti A, Garcia-Pagan JC. The clinical
use of HVPG measurements in chronic liver disease. Nature reviews
Gastroenterology & hepatology 2009; 6 (10): 573-82.
18. Wong YJ, Zhaojin C, Tosetti G, et al. Baveno-VII criteria to predict
decompensation and initiate non-selective beta-blocker in compensated
advanced chronic liver disease patients. Clinical and molecular
hepatology 2022.
19. European Association for the Study of the Liver. Electronic address
eee, Clinical Practice Guideline P, Chair, representative EGB, Panel m.
EASL Clinical Practice Guidelines on non-invasive tests for evaluation
of liver disease severity and prognosis - 2021 update. Journal of
hepatology 2021; 75 (3): 659-89.
20. Qi X, An W, Liu F, et al. Virtual Hepatic Venous Pressure Gradient
with CT Angiography (CHESS 1601): A Prospective Multicenter Study for
the Noninvasive Diagnosis of Portal Hypertension. Radiology 2019;290 (2): 370-7.
21. Liu Y, Ning Z, Ormeci N, et al. Deep Convolutional Neural
Network-Aided Detection of Portal Hypertension in Patients With
Cirrhosis. Clinical gastroenterology and hepatology : the official
clinical practice journal of the American Gastroenterological
Association 2020; 18 (13): 2998-3007 e5.
22. Ripoll C, Groszmann R, Garcia-Tsao G, et al. Hepatic venous pressure
gradient predicts clinical decompensation in patients with compensated
cirrhosis. Gastroenterology 2007; 133 (2): 481-8.
23. Yu Q, Xu C, Li Q, et al. Spleen volume-based non-invasive tool for
predicting hepatic decompensation in people with compensated cirrhosis
(CHESS1701). JHEP Rep 2022; 4 (11): 100575.
24. Gidener T, Ahmed OT, Larson JJ, et al. Liver Stiffness by Magnetic
Resonance Elastography Predicts Future Cirrhosis, Decompensation, and
Death in NAFLD. Clinical gastroenterology and hepatology : the
official clinical practice journal of the American Gastroenterological
Association 2021; 19 (9): 1915-24 e6.
25. Liu Y, Liu C, Li J, Kim TH, Enomoto H, Qi X. Risk stratification of
decompensation using liver stiffness and platelet counts in compensated
advanced chronic liver disease (CHESS2102). Journal of hepatology2022; 76 (1): 248-50.
26. Wong YJ, Li J, Liu C, et al. CHESS-ALARM score to stratify
decompensation risk in compensated advanced chronic liver disease
patients: An international multicenter study. Journal of
gastroenterology and hepatology 2022; 37 (6): 1043-51.
27. Garcia-Tsao G, Abraldes JG. Nonselective Beta-Blockers in
Compensated Cirrhosis: Preventing Variceal Hemorrhage or Preventing
Decompensation? Gastroenterology 2021; 161 (3): 770-3.
28. Villanueva C, Torres F, Sarin SK, et al. Carvedilol reduces the risk
of decompensation and mortality in patients with compensated cirrhosis
in a competing-risk meta-analysis. Journal of hepatology 2022;77 (4): 1014-25.
29. Serper M, Kaplan DE, Taddei TH, Tapper EB, Cohen JB, Mahmud N.
Nonselective beta blockers, hepatic decompensation, and mortality in
cirrhosis: A national cohort study. Hepatology 2022.
30. Groszmann RJ, Garcia-Tsao G, Bosch J, et al. Beta-blockers to
prevent gastroesophageal varices in patients with cirrhosis. The
New England journal of medicine 2005; 353 (21): 2254-61.